Somatostatin receptor imaging (SRI) with [111 In-DTPA 0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs) …

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …

Nuclear medicine plays a pivotal role in the imaging and treatment of neuroendocrine
tumours (NETs). Somatostatin receptor scintigraphy (SRS) with [111 In-DTPA 0] octreotide …

Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

Somatostatin receptor PET tracers such as [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-
DOTANOC) and [68Ga-DOTA, Tyr3]-octreotate (68Ga-DOTATATE) have shown promising …

Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of
neuroendocrine tumor. Because detection of distant metastases has a major impact on …

Somatostatin receptor imaging with [111In-DTPA0) octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors. Treatment with …

The use of positron emitter–labeled compounds for somatostatin receptor imaging (SRI) has
become attractive because of the prospect of improved spatial resolution, accelerated …

PURPOSE:[111In]-DTPAOC (Octreoscan®) has been shown to be very useful in the
detection of somatostatin receptor (SSTR) positive tumors and their metastases using either …

Abstract Treatment with radiolabelled somatostatin analogues is a promising new tool in the
management of patients with inoperable or metastasized neuroendocrine tumours …